Status:
COMPLETED
The Safety and Efficacy of Psilocybin in Participants With Treatment Resistant Depression
Lead Sponsor:
COMPASS Pathways
Conditions:
Treatment Resistant Depression
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
The Safety and Efficacy of Psilocybin in Participants with Treatment Resistant Depression
Detailed Description
The Safety and Efficacy of Psilocybin in Participants with Treatment Resistant Depression - a dose-ranging study
Eligibility Criteria
Inclusion
- Diagnosis of TRD
Exclusion
- Other comorbidities
Key Trial Info
Start Date :
March 1 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 27 2021
Estimated Enrollment :
233 Patients enrolled
Trial Details
Trial ID
NCT03775200
Start Date
March 1 2019
End Date
September 27 2021
Last Update
April 24 2023
Active Locations (25)
Enter a location and click search to find clinical trials sorted by distance.
1
Kadima Neuropsychiatry Institute
La Jolla, California, United States, 92037
2
Altman Clinical and Translational Research Institute, University of California
San Diego, California, United States, 92093
3
Stanford Department of Psychiatry
Stanford, California, United States, 94305
4
Mood and Anxiety Disorders Program Emory University School of Medicine
Atlanta, Georgia, United States, 30329